NeoGenomics Inc (NEO)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $2.07B
Last updated: Nov 17, 2026 at 11:06 AM ET
NeoGenomics Inc (NEO) Earnings: Report Dates and Results
NeoGenomics (NEO) is expected to report earnings on Feb 15, 2027. In the quarter ended Sep 30, 2026, NeoGenomics reported EPS of $0.01, above the -$0.01 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NEO has an expected report date of Feb 15, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 16.7% above the $0.06 reported for the quarter ended Dec 31, 2025.
NEO Earnings Call
The latest NEO earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 37 quarters below that had an estimate, NEO beat 32, missed 4 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $209.25M, up 11.4% from $187.80M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.01 | -$0.01 | N/A | +200.00% | Beat | -66.7% | 11 | 2 up, 1 down | Oct 28, 2026 | $209.25M |
| Jun 30, 2026 | -$0.01 | -$0.06 | N/A | +83.33% | Beat | -133.3% | 11 | 0 up, 1 down | Jul 28, 2026 | $201.66M |
| Mar 31, 2026 | $0.01 | $0.01 | -$0.03 - $0.02 | -12.28% | Miss | N/A | 9 | 1 up, 5 down | Apr 28, 2026 | $186.67M |
| Dec 31, 2025 | $0.06 | $0.04 | $0.01 - $0.06 | +50.00% | Beat | +50.0% | 12 | 1 up, 0 down | Feb 17, 2026 | $190.17M |
| Sep 30, 2025 | $0.03 | $0.02 | $0.01 - $0.05 | +50.00% | Beat | N/A | 13 | 0 up, 12 down | Oct 28, 2025 | $187.80M |
| Jun 30, 2025 | $0.03 | $0.02 | $0.01 - $0.06 | +50.00% | Beat | 0.0% | 13 | 0 up, 2 down | Jul 29, 2025 | $181.33M |
| Mar 31, 2025 | -$0.20 | -$0.01 | -$0.02 - $0.03 | N/A | N/A | N/A | 12 | 0 up, 1 down | Apr 29, 2025 | $168.03M |
| Dec 31, 2024 | $0.04 | $0.03 | $0.01 - $0.07 | +39.86% | Beat | +33.3% | 14 | 1 up, 0 down | Feb 18, 2025 | $172.00M |
| Sep 30, 2024 | -$0.14 | $0.01 | -$0.03 - $0.05 | N/A | N/A | N/A | 14 | 1 up, 0 down | Nov 5, 2024 | $167.82M |
| Jun 30, 2024 | $0.03 | $0.00 | -$0.03 - $0.02 | N/A | N/A | N/A | 13 | 0 up, 0 down | Jul 29, 2024 | $164.50M |
| Mar 31, 2024 | -$0.02 | -$0.05 | -$0.11 - -$0.02 | +60.00% | Beat | N/A | 11 | 0 up, 0 down | Apr 30, 2024 | $156.24M |
| Dec 31, 2023 | $0.03 | -$0.03 | -$0.10 - $0.00 | +200.00% | Beat | N/A | 13 | 1 up, 0 down | Feb 20, 2024 | $155.55M |
| Sep 30, 2023 | -$0.02 | -$0.08 | -$0.16 - -$0.05 | +75.00% | Beat | N/A | 12 | 1 up, 0 down | Nov 6, 2023 | $151.95M |
| Jun 30, 2023 | -$0.05 | -$0.11 | -$0.15 - -$0.08 | +54.55% | Beat | N/A | 13 | 1 up, 0 down | Aug 8, 2023 | $146.92M |
| Mar 31, 2023 | -$0.09 | -$0.15 | -$0.27 - -$0.06 | +40.00% | Beat | N/A | 13 | 1 up, 0 down | May 8, 2023 | $137.22M |
| Dec 31, 2022 | -$0.06 | -$0.16 | -$0.27 - -$0.10 | +62.50% | Beat | N/A | 13 | 0 up, 0 down | Feb 23, 2023 | $138.71M |
| Sep 30, 2022 | -$0.14 | -$0.21 | -$0.25 - -$0.15 | +33.33% | Beat | N/A | 13 | 1 up, 0 down | Nov 8, 2022 | $128.78M |
| Jun 30, 2022 | -$0.16 | -$0.23 | -$0.28 - -$0.16 | +30.43% | Beat | N/A | 13 | 0 up, 0 down | Aug 9, 2022 | $125.07M |
| Mar 31, 2022 | -$0.20 | -$0.24 | -$0.29 - -$0.18 | +16.67% | Beat | N/A | 12 | 0 up, 1 down | Apr 27, 2022 | $117.17M |
| Dec 31, 2021 | -$0.14 | -$0.15 | -$0.22 - -$0.10 | +6.67% | Beat | -200.0% | 11 | N/A | Feb 23, 2022 | $125.73M |
| Sep 30, 2021 | -$0.08 | -$0.09 | -$0.14 - -$0.01 | +11.11% | Beat | -233.3% | 12 | N/A | Nov 4, 2021 | $121.34M |
| Jun 30, 2021 | -$0.01 | -$0.06 | -$0.13 - $0.01 | +83.33% | Beat | N/A | 12 | N/A | Aug 6, 2021 | $121.72M |
| Mar 31, 2021 | -$0.04 | $0.01 | -$0.03 - $0.04 | -500.00% | Miss | N/A | 11 | N/A | May 5, 2021 | $115.53M |
| Dec 31, 2020 | $0.14 | $0.06 | $0.03 - $0.09 | +133.33% | Beat | +40.0% | 11 | N/A | Feb 24, 2021 | $126.00M |
| Sep 30, 2020 | $0.06 | $0.04 | -$0.06 - $0.11 | +50.00% | Beat | -14.3% | 10 | N/A | Oct 27, 2020 | $125.44M |
| Jun 30, 2020 | -$0.04 | -$0.10 | -$0.17 - -$0.05 | +60.00% | Beat | -157.1% | 8 | N/A | Jul 28, 2020 | $86.98M |
| Mar 31, 2020 | -$0.02 | $0.02 | $0.01 - $0.03 | -200.00% | Miss | -128.6% | 9 | N/A | Apr 28, 2020 | $106.03M |
| Dec 31, 2019 | $0.10 | $0.06 | $0.05 - $0.09 | +66.67% | Beat | +66.7% | 7 | N/A | Feb 27, 2020 | $106.87M |
| Sep 30, 2019 | $0.07 | $0.06 | $0.05 - $0.07 | +16.67% | Beat | +40.0% | 8 | N/A | Oct 29, 2019 | $104.67M |
| Jun 30, 2019 | $0.07 | $0.06 | $0.05 - $0.07 | +16.67% | Beat | +40.0% | 8 | N/A | Jul 30, 2019 | $101.71M |
| Mar 31, 2019 | $0.07 | $0.04 | $0.03 - $0.07 | +75.00% | Beat | +75.0% | 8 | N/A | Apr 30, 2019 | $95.58M |
| Dec 31, 2018 | $0.06 | $0.04 | $0.04 - $0.08 | +50.00% | Beat | +20.0% | 9 | N/A | Feb 19, 2019 | $76.47M |
| Sep 30, 2018 | $0.05 | $0.02 | $0.01 - $0.04 | +150.00% | Beat | +400.0% | 8 | N/A | Oct 30, 2018 | $69.10M |
| Jun 30, 2018 | $0.05 | $0.04 | $0.04 - $0.05 | +25.00% | Beat | +25.0% | 6 | N/A | Jul 24, 2018 | $67.75M |
| Mar 31, 2018 | $0.04 | $0.03 | $0.03 - $0.03 | +33.33% | Beat | +33.3% | 6 | N/A | May 1, 2018 | $63.42M |
| Dec 31, 2017 | $0.05 | $0.04 | $0.03 - $0.05 | +25.00% | Beat | 0.0% | 8 | N/A | Feb 21, 2018 | $67.79M |
| Sep 30, 2017 | $0.01 | $0.02 | $0.01 - $0.05 | -50.00% | Miss | -75.0% | 9 | N/A | Oct 25, 2017 | $63.05M |
| Jun 30, 2017 | $0.04 | $0.03 | $0.03 - $0.04 | +33.33% | Beat | 0.0% | 9 | N/A | Jul 25, 2017 | $62.26M |
| Mar 31, 2017 | $0.03 | $0.03 | N/A | 0.00% | In line | 0.0% | N/A | N/A | Apr 26, 2017 | $61.68M |
| Dec 31, 2016 | $0.05 | $0.03 | N/A | +66.67% | Beat | N/A | N/A | N/A | Feb 22, 2017 | $60.49M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.08, after -$0.09 the year before. It was $0.16 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.08 | N/A |
| Dec 31, 2024 | -$0.09 | N/A |
| Dec 31, 2023 | -$0.13 | N/A |
| Dec 31, 2022 | -$0.56 | N/A |
| Dec 31, 2021 | -$0.27 | -292.9% |
| Dec 31, 2020 | $0.14 | -54.8% |
| Dec 31, 2019 | $0.31 | +55.0% |
| Dec 31, 2018 | $0.20 | +53.8% |
| Dec 31, 2017 | $0.13 | N/A |
| Dec 31, 2016 | $0.16 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 11,000 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 10,575 | 16 | |
| 2026Q2 | Jun 30, 2026 | 7,721 | 14 | |
| 2026Q1 | Mar 31, 2026 | 7,306 | 14 | |
| 2025Q4 | Dec 31, 2025 | 6,619 | 10 | |
| 2025Q3 | Sep 30, 2025 | 7,883 | 15 | |
| 2025Q2 | Jun 30, 2025 | 9,712 | 17 | |
| 2025Q1 | Mar 31, 2025 | 9,647 | 19 | |
| 2024Q4 | Dec 31, 2024 | 9,221 | 18 |
2026Q3 Earnings Call
Opening remarks
Andrew Brackmann Vice President of Investor Relations Thank you, Sylvie, and good afternoon, everyone. Representing NeoGenomics here today are Tony Zook, Chief Executive Officer; Warren Stone, President and Chief Operating Officer; and Abhishek Jain, Chief Financial Officer. This call is being simultaneously webcast, and a recording will be available following the conclusion at ir.neogenomics.com. During this call, we will make forward-looking statements regarding our future financial and business performance, our planned leadership transition, planned future operations and related expectations with respect to timing and performance, future financial position, future revenues, growth potential and expected growth drivers, projected costs and capital expenditures, prospects and plans, estimates of market size and position, the implementation of our new revenue cycle management platform and its anticipated benefits and effects on the timing of our collections, objectives of management, and financial guidance. We caution you that the actual events or results could differ materially from those expressed or implied by the forward-looking statements. These forward-looking statements made during the call speak only as of the original date of this call, and we undertake no obligation to update or revise any of these statements. Please refer to the information disclosed on the safe harbor statement slide in the deck posted on our website, as well as the information under the heading Risk Factors in our annual report on Form 10-K and our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with the SEC, to identify important risks and other factors that may cause our actual results to differ materially from the forward-looking statements. These documents can be found in the Investors section of our website or on the SEC's website. During this call, we will also refer to certain non-GAAP financial measures that involve adjustments to our GAAP results. The non-GAAP financial measures presented should not be considered an alternative to the financial measures required by GAAP, should not be considered measures of liquidity, and are unlikely to be comparable to the non-GAAP financial measures provided by other companies. Any non-GAAP financial measures referenced on this call are reconciled to the most directly comparable GAAP financial measures in a table available in the press release we issued earlier today and in the slide deck available in the Investors section of our website. I will now turn the call over to Tony.
Anthony Zook Chief Executive Officer Thank you, Andrew, and good afternoon, everyone. We're excited to report another strong quarter, which shows we have the right strategy in place, the right team to execute it, and we're delivering consistent results because of this. Our business is continuing to gain momentum, and our third-quarter results show it. Clinical revenue grew 13% year over year.
Frequently Asked Questions About NEO
When is NeoGenomics's next earnings date?
NeoGenomics's next earnings report is expected for Feb 15, 2027.
Did NEO beat earnings estimates last quarter?
Yes. NeoGenomics reported EPS of $0.01 for the quarter ended Sep 30, 2026, above the -$0.01 estimate, a 200.00% surprise.
What EPS do analysts expect from NEO next quarter?
The consensus EPS estimate for NeoGenomics for the quarter ending Dec 31, 2026 is $0.07 from 13 analysts, with estimates from $0.05 to $0.09.
How often does NEO beat earnings estimates?
NeoGenomics beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +65.11%.
NEO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts